@article{30e1d19a2a4e4c5d982799c9cac286d7,
title = "Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): a multicentre randomised controlled trial",
abstract = "Background It remains unclear whether urgent endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy improves the outcome of patients with gallstone pancreatitis without concomitant cholangitis. We did a randomised trial to compare urgent ERCP with sphincterotomy versus conservative treatment in patients with predicted severe acute gallstone pancreatitis.Methods In this multicentre, parallel-group, assessor-masked, randomised controlled superiority trial, patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score >= 8, Imrie score >= 3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands. Patients were randomly assigned (1:1) by a web-based randomisation module with randomly varying block sizes to urgent ERCP with sphincterotomy (within 24 h after hospital presentation) or conservative treatment. The primary endpoint was a composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency) within 6 months of randomisation. Analysis was by intention to treat. This trial is registered with the ISRCTN registry, ISRCTN97372133.Findings Between Feb 28, 2013, and March 1, 2017, 232 patients were randomly assigned to urgent ERCP with sphincterotomy (n=118) or conservative treatment (n=114). One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission. The primary endpoint occurred in 45 (38%) of 117 patients in the urgent ERCP group and in 50 (44%) of 113 patients in the conservative treatment group (risk ratio [RR] 0.87, 95% CI 0.64-1.18; p=0.37). No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0.18, 95% CI 0.04-0.78; p=0.010). Adverse events were reported in 87 (74%) of 118 patients in the urgent ERCP group versus 91 (80%) of 114 patients in the conservative treatment group.Interpretation In patients with predicted severe gallstone pancreatitis but without cholangitis, urgent ERCP with sphincterotomy did not reduce the composite endpoint of major complications or mortality, compared with conservative treatment. Our findings support a conservative strategy in patients with predicted severe acute gallstone pancreatitis with an ERCP indicated only in patients with cholangitis or persistent cholestasis.",
keywords = "acute biliary pancreatitis, acute cholangitis, acute necrotizing pancreatitis, clinical-trials, disease, early ductal decompression, epidemiology, management, obstruction, pathogenesis, MANAGEMENT, ACUTE BILIARY PANCREATITIS, EARLY DUCTAL DECOMPRESSION, PATHOGENESIS, CLINICAL-TRIALS, OBSTRUCTION, DISEASE, ACUTE NECROTIZING PANCREATITIS, ACUTE CHOLANGITIS, EPIDEMIOLOGY",
author = "N.J. Schepers and N.D.L. Hallensleben and M.G. Besselink and M.P.G.F. Anten and T.L. Bollen and {da Costa}, D.W. and {van Delft}, F. and {van Dijk}, S.M. and {van Dullemen}, H.M. and M.G.W. Dijkgraaf and {van Eijck}, C.H.J. and G.W. Erkelens and N.S. Erler and P. Fockens and {van Geenen}, E.J.M. and {van Grinsven}, J. and R.A. Hollemans and {van Hooft}, J.E. and {van der Hulst}, R.W.M. and J.M. Jansen and F.J.G.M. Kubben and S.D. Kuiken and R.J.F. Laheij and R. Quispel and {de Ridder}, R.J.J. and M.C.M. Rijk and T.E.H. Romkens and C.H.M. Ruigrok and E.J. Schoon and M.P. Schwartz and X.J.N.M. Smeets and B.W.M. Spanier and A.C.I.T.L. Tan and W.J. Thijs and R. Timmer and N.G. Venneman and R.C. Verdonk and F.P. Vleggaar and {van de Vrie}, W. and B. Witteman and {van Santvoort}, H.C. and O.J. Bakker and M.J. Bruno and {Dutch Pancreatitis Study Grp}",
note = "Funding Information: This trial was funded by the Netherlands Organization for Health Research and Development (Health Care Efficiency Research programme, grant number 837002008), Fonds NutsOhra (grant number 1203-052), and the Dutch Patient Organization for Pancreatic Diseases. Funding Information: NJS reports grants from ZonMw and Fonds NutsOhra, during the conduct of the study. PF reports grants from Boston Scientific, and personal fees from Olympus, Cook, and Ethicon Endosurgery, outside the submitted work. MJB reports grants from ZonMw and Fonds NutsOhra, during the conduct of the study; and personal fees from Boston Scientific, Cook Medical, Pentax Medical, and Mylan, and grants from Boston Scientific, Cook Medical, Pentax Medical, 3M, and Mylan, outside the submitted work. All other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2020",
month = jul,
day = "18",
doi = "10.1016/S0140-6736(20)30539-0",
language = "English",
volume = "396",
pages = "167--176",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Science",
number = "10245",
}